Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Total Non-Current Liabilities (2016 - 2025)

Mimedx's Total Non-Current Liabilities history spans 15 years, with the latest figure at $80.7 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 27.29% year-over-year to $80.7 million; the TTM value through Dec 2025 reached $80.7 million, up 27.29%, while the annual FY2025 figure was $80.7 million, 27.29% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $80.7 million at Mimedx, up from $74.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $191.0 million in Q2 2021 and bottomed at -$3.9 million in Q3 2023.
  • The 5-year median for Total Non-Current Liabilities is $71.0 million (2025), against an average of $78.2 million.
  • The largest YoY upside for Total Non-Current Liabilities was 6219.96% in 2023 against a maximum downside of 128.05% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $90.5 million in 2021, then grew by 1.84% to $92.2 million in 2022, then increased by 2.12% to $94.1 million in 2023, then crashed by 32.6% to $63.4 million in 2024, then grew by 27.29% to $80.7 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Total Non-Current Liabilities are $80.7 million (Q4 2025), $74.5 million (Q3 2025), and $67.5 million (Q2 2025).